Administration of radium‐223 and the prognosis in Japanese bone metastatic castration‐resistant prostate cancer patients: A large database study

BACKGROUND: The ALSYMPCA trial revealed radium‐223 (Ra‐223) to be a life‐prolonging agent for bone metastatic castration‐resistant prostate cancer (CRPC). However, only 2.8% of enrolled patients in that clinical trial were Asian, and no Japanese patients were enrolled. Several retrospective studies...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawahara, Takashi, Miyoshi, Yasuhide, Ninomiya, Sahoko, Sato, Motoki, Takeshima, Teppei, Hasumi, Hisashi, Makiyama, Kazuhide, Uemura, Hiroji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles: Clinical Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9544379/
https://www.ncbi.nlm.nih.gov/pubmed/35976620
http://dx.doi.org/10.1111/iju.15008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9544379/
https://www.ncbi.nlm.nih.gov/pubmed/35976620
http://dx.doi.org/10.1111/iju.15008

Ejemplares similares